Zhen-Ao Group of China showcased its latest breakthroughs in 5'-nucleotide anti-aging research at the international academic conference "Frontiers in Aging, Longevity and Regeneration," held at the University of Cambridge on April 8. Invited as a key research representative, the company highlighted its growing role in the global longevity and regenerative medicine ecosystem while presenting a Chinese pathway for technology-driven anti-aging solutions.
The conference brought together leading experts from around the world to explore the latest advances in aging intervention and regenerative medicine. It was jointly organized by the European Academy of Nutritional, Food and Behavioral Health Sciences and the Luxembourg Academy of Sciences and Arts. Distinguished attendees included May-Britt Moser, recipient of the 2014 Nobel Prize in Physiology or Medicine; Professor James Rowe, Director of the Cambridge Centre for Frontotemporal Dementia and Related Disorders; and Professor Jiong Wu, Member of the Luxembourg Academy of Sciences and Arts.
Zhen-Ao Group has been deeply engaged in nucleotide-based anti-aging research for many years. Its research achievements have been reported twice by the Associated Press, and it received the 2025 Heidelberg Eurasian International Life Forum Award for Nucleotide R&D Technology. Recognized for its internationally leading capabilities, the Group was invited to participate in the conference.
At the conference, Zhen-Ao Group presented its core achievements from two decades of research on exogenous 5'-nucleotides, demonstrating China’s strength in nutritional anti-aging technology and offering the world a practical, verifiable solution for technology-driven anti-aging.
Commissioned by Zhen-Ao Group, Peking University spent 20 years achieving a full-chain breakthrough in 5'-nucleotide anti-aging research, building a comprehensive evidence-based system spanning “molecule — cell — animal — human” studies and delivering world-leading clinical and scientific results.
The two parties completed a randomized, double-blind, placebo-controlled human clinical trial. Following a 19-week intervention in 121 subjects aged 60–70 years, the 5'-nucleotides group demonstrated a 3.08-year reversal in DNA methylation age, along with significant improvements in insulin sensitivity, increases in skeletal muscle mass, reductions in trunk fat mass and visceral fat grade, and marked alleviation of physical fatigue.
These findings were published in 2025 in Advanced Science, a leading international journal with an impact factor of 14.3. The study represents the world’s first comprehensive, evidence-based human clinical trial investigating the anti-aging effects of exogenous nucleotides, marking a shift toward quantifiable and verifiable clinical practice in nutritional interventions for aging.
Preclinical animal studies further showed that 5'-nucleotides extended the median survival of SAMP8 mice by 9.21% to 12.6%, equivalent to an approximate 8.76 to 12.01-year extension in human lifespan. The compounds also comprehensively ameliorated age-related phenotypes across multiple tissues and organ systems, systematically enhancing healthy lifespan and quality of life.
At the mechanistic level, 5'-nucleotides target the core processes of cellular senescence by repairing DNA damage, upregulating telomerase activity, mitigating oxidative stress, reshaping mitochondrial energy metabolism, activating autophagy to remove senescent cells, and suppressing chronic age-related inflammation, thereby restoring cellular vitality and supporting overall health.
A multi-generation rat safety study initiated in 2006 confirmed that exogenous 5'-nucleotide supplementation is safe and well-tolerated, establishing a solid foundation for long-term dietary consumption.
Leveraging its patented enzymatic hydrolysis technology for food yeast, Zhen-Ao Group manufactures high-purity 5'-nucleotides at large scale in compliance with U.S. FCC quality standards. This creates a closed-loop system of “R&D — technology — commercialization,” enabling the efficient translation of scientific discoveries into practical nutritional solutions and providing a model for the industrialization of nucleotide-based anti-aging worldwide.
Experts at the conference praised Zhen-Ao Group’s multidimensional and systematic anti-aging framework, noting that its integrated industry-academia-research model offers innovative solutions for global healthy aging and the advancement of regenerative medicine.
This appearance in Cambridge marks a significant milestone for Chinese life science companies transitioning from technology followers to global leaders. Looking ahead, Zhen-Ao Group will continue to deepen its nucleotide research, promote global adoption of its anti-aging solutions, and contribute to improving health span and quality of life worldwide.
Media Contact
Zitian Geng
housb@zhenao-gp.com
